Stem cells are pluripotent cells with the ability to replicate themselves. Under certain conditions, it can differentiate into a variety of functional cells. Stem cell therapy is the extraction of stem cells from the patient's own bone marrow by cell biology methods, and the stem cells are extracted from the bodyexternally. They are isolated and then transplanted into the patient's body. After a period of development and maturation, they become functional stem cells to replenish and repair damaged or defective tissue.  

Stem cells are pluripotent cells with self-renewal ability, which can differentiate into cells with various functions and Tissues and organs are widely present in various tissues and organs of the body, such as bone marrow, peripheral blood, early embryos and adult tissues. According to their differentiation potential, stem cells are generally divided into three types: totipotent stem cells, pluripotent stem cells and single stem cells. able stem cells.  

Stem cell therapy refers to the replacement of diseased tissues and organs with stem cell-derived tissues or organs for spinal cord injury, diabetes, Diseases that cannot be treated by traditional medical methods, such as ischemic heart disease. The stem cell medical industry is an entire industry including stem cell extraction, stem cell storage, stem cell product development and stem cell therapy. 1Product Type Analysis 

1.1 Stem Cell Storage 

Cell Storage The APSC pluripotent cells in the cells are stored for a certain period of time by certain methods to ensure that the function and activity of the cells are not Affected by obvious influence, it is the most basic and front-end business in the stem cell medical industry, and it is also the place where the most capital is gathered. The main representative companies include: Tianjin Cord Blood Hematopoietic Stem Cell Bank of Zhongyuan Xiehe, China Cord Blood Bank of Jinwei Medical, Shanghai Cord Blood Hematopoietic Stem Cell Bank of Shanghai Stem Cell Technology Company, Boya Stem Cell Mesenchymal Stem Cell Bank of Jiangsu Province, Guangdong Provincial umbilical cord blood hematopoietic stem cell bank and Shandong human umbilical cord mesenchymal stem cell bank, etc. Stem cell storage is to separate and culture stem cells from different human tissues, then test and identify them, and then freeze them at -196°C, so that stem cells can be resuscitated for return to patients when clinically needed. lose, to achieve the purpose of curing disease.

 1.2 Stem Cell Pharmacy & Treatment 

Stem cell therapy can be divided into stem cell transplantation therapy and stem cell injection therapy according to the type of treatment. Bone marrow transplantation is essentially stem cell transplantation therapy; stem cell therapy for cartilage repair is stem cell injection therapy, and stem cell injection therapy will be a trend in the future. Stem cell therapy can be used for disease treatment in the fields of repairing tissue cell damage and replacing the function of damaged cells; using in vitro cultured and expanded stem cells to cultivate human tissues and organs for organ transplantation and bioremediation of autoimmune diseases. The main representative is the tertiary hospital. Stem cell products mainly include stem cell storage and stem cell pharmaceuticals and treatments. Among them, stem cell pharmaceuticals and treatments account for the largest proportion. In 2021, the market share will reach 56.56%, and the sales will be US$546.57 million.

 China's stem cell market status quo and development trend analysis 

According to QYR's latest research, the sales revenue of China's stem cell market will reach US$966.4 million in 2021, and it is expected to reach 3030 million in 2028. USD 10,000, with a compound annual growth rate (CAGR) of 17.92% during 2022-2028.  

 The future development prospects of stem cell therapy in China are very promising, mainly as follows: 

The market demand is huge 

In recent years, cell therapy has become the most cutting-edge tumor treatment method, attracting the attention of the global medical market. my country is also starting from the regulatory policy to find out the direction for the industrialization of cell therapy. At the same time, the regulations of "limited release of stem cell clinical research" and "cell products are managed according to drugs" indicate that the mid- and downstream industries of stem cells have begun to accelerate.  

Patient acceptance of stem cell therapy is gradually improving 

In recent years, with the continuous development of stem cell therapy technology, patients' acceptance of stem cell therapy is gradually improving. Stem cell-based therapies are believed to offer new hope for serious chronic diseases such as colitis, diabetes, arthritis, cirrhosis, kidney disease, heart disease, chronic obstructive pulmonary disease, and more. With the development of research, the range of diseases that stem cells can treat is gradually being revealed. It is worth mentioning that the list of diseases that it can treat is constantly increasing.  

Stem cell therapy holds broad medical prospects 

Clinical studies of stem cell therapy cover more than 140 diseases. In the total global stem cell market, cell therapy occupies half of the country and has a tendency to further expand. Overall, the application of stem cell technology has broad prospects, and the proportion of stem cell therapy will be further expanded. The therapy is widely used in the field of disease treatment due to its advantages of proliferation and differentiation. The upstream of the industry chain is mainly stem cell collection and storage companies. Cell storage stores APSC pluripotent cells in cells for a certain period of time through a certain method to ensure that the function and activity of cells are not significantly affected. The main representative companies include: Tianjin Cord Blood Hematopoietic Stem Cell Bank of Zhongyuan Xiehe, China Cord Blood Bank of Jinwei Medical, Shanghai Cord Blood Hematopoietic Stem Cell Bank of Shanghai Stem Cell Technology Company, Boya Stem Cell Mesenchymal Stem Cell Bank of Jiangsu Province, Guangdong Provincial umbilical cord blood hematopoietic stem cell bank and Shandong human umbilical cord mesenchymal stem cell bank, etc.  

The midstream of the stem cell industry chain is a stem cell proliferation and drug research and development enterprise. The downstream is composed of institutions that carry out stem cell medical treatment, mainly tertiary hospitals. At present, stem cell therapy can be used for disease treatment in the fields of repairing tissue cell damage and replacing the function of damaged cells; using in vitro cultured and expanded stem cells to cultivate human tissues and organs for organ transplantation and bioremediation of autoimmune diseases. The downstream application markets of stem cell products are mainly hematological diseases, cancer, autoimmune diseases and others. Among them, blood diseases account for the largest proportion, and in 2021, the market share will reach 73.23%. At present, the main Chinese manufacturers include the core manufacturers in the Chinese market, including International Cord Blood Bank, Zhongyuan Concord, Boya Holding Group, Beike Bio, Han's United Group and Qingdao Aoke Bio, etc. The top three manufacturers in 2021 will occupy about 32.34% of the market share.  

 Stem Cell Industry Supply Chain Analysis 

 [Upstream situation] It is mainly stem cell storage, the most mature part. Upstream of the industry chain are mainly stem cell collection and storage companies. Cell storage stores APSC pluripotent cells in cells for a certain period of time through a certain method to ensure that the function and activity of cells are not significantly affected. The main representative companies include: Tianjin Cord Blood Hematopoietic Stem Cell Bank of Zhongyuan Xiehe, China Cord Blood Bank of Jinwei Medical, Shanghai Cord Blood Hematopoietic Stem Cell Bank of Shanghai Stem Cell Technology Company, Boya Stem Cell Mesenchymal Stem Cell Bank of Jiangsu Province, Guangdong Provincial umbilical cord blood hematopoietic stem cell bank and Shandong human umbilical cord mesenchymal stem cell bank, etc.  

[Stem cell industry situation] The midstream of the stem cell industry chain is a stem cell proliferation and drug research and development enterprise, mainly engaged in technology research and development, including stem cell proliferation , stem cell drug research and development, laboratory processing supporting products (such as detection reagents), etc. Zhongyuan Xiehe, Boya Holdings, Kyushu Group, AVIC Biology, Maijian Biology and other companies are involved in this business.

 [Downstream situation] Downstream consists of institutions that carry out stem cell medical treatment, mainly tertiary hospitals. At present, stem cell therapy can be used for disease treatment in the fields of repairing tissue cell damage and replacing the function of damaged cells; using in vitro cultured and expanded stem cells to cultivate human tissues and organs for organ transplantation and bioremediation of autoimmune diseases. In addition, in the field of consumer-grade applications, stem cells can also be used for medical cosmetology to delay cell aging.